Securities Analyst Recommendations: Centrais Eletricas Brasileiras S.A. – Eletrobras (EBR), Taro Pharmaceutical Industries Ltd. (TARO)

Centrais Eletricas Brasileiras S.A. – Eletrobras (NYSE:EBR) tinted gains of +0.94% (+0.09 points) to US$9.62. The volume of 0.38 Million shares climbed down over an trading activity of 615.83 Million shares. EPS ratio determined by looking at last 12 month figures is -0.54. Over the same time span, the stock marked US$10.46 as its best level and the lowest price reached was US$3.14. The corporation has a market cap of US$13.01 Billion.

Centrais Eletricas Brasileiras S.A. – Eletrobras (NYSE:EBR)’s earnings per share has been growing at a 0 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at 0 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 2.84 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) is worth US$3.98 Billion and has recently risen 0.45% to US$104.75. The latest exchange of 0.11 Million shares is below its average trading activity of 65.54 Million shares. The day began at US$104.94 but the price moved to US$104.03 at one point during the trading and finally capitulating to a session high of US$105.9. The stock tapped a 52-week high of US$106.94 while the mean 12-month price target for the shares is US$101.16.

Currently, the stock carries a price to earnings ratio of 17.65, a price to book ratio of 2.22, and a price to sales ratio of 6.17. For the past 5 years, the company’s revenue has grown -0.3%, while the company’s earnings per share has grown -2.5%. With an institutional ownership near 11.7%, it carries an earnings per share ratio of 5.93.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.5.